Successful treatment of a giant ossified benign mesenteric schwannoma

Table 1 Clinical characteristics of the 10 patients with mesenteric schwannomas

Ref.	Year	Sex/Age	Symptom	Imaging method	Size(cm)	Preoperative diagnosis	Treatment	Histology	Follow-up (mo)	Status
Present case	2017	F/58	Asymptomatic	US, CT, MRI	10 × 9 × 9	Teratoma	Surgery	Benign	43	Survived
Medina-Gallardo et al[7]	2017	F/80	Asymptomatic	CT	NA	NA	Laparoscopic operation	Benign	NA	NA
Tepox Padrón et al[8]	2017	F/38	Asymptomatic	MRI	11.3 × 8.4 × 4.1	NA	Surgery	Benign	24	Survived
Wang et al[8]	2014	M/54	Abdominal pain and hematochezia	CT, Colonoscopy	NA	NA	Ascending, transverse and splenic flexure colectomy	Benign	12	Survived
Tang et al[8]	2014	F/43	Mild abdominal pain	CT	4.0 × 4.0 × 1.9	GIST or leiomyoma	Laparoscopic operation	Benign	10	Survived
Lao et al[8]	2011	M/45	Asymptomatic	CT, MRI and Angiography	2.2 × 1.7	NA	Surgical excision	Benign	NA	NA
Kilicoglu et al[8]	2006	M/56	Nausea, vomiting, abdominal pain, and constipation	US	22 × 19 × 4	Intra-abdominal mass	Surgery	Benign	11	Survived
Minami et al[8]	2005	F/54	Asymptomatic	CT, MRI	8.0 × 7.0 × 4.8	Benign solid tumour	Enucleation	Benign	5	Survived
Ramboer et al[8]	1998	NA	Asymptomatic	MRI	NA	NA	NA	Benign	NA	NA
Murakami et al[8]	1998	M/48	Asymptomatic	United States, CT, MRI	4.5 × 4.0 × 4.0	Benign solid tumour	Laparotomy	Benign	24	Survived

M: Male; F: Female; NA: Not available; US: Ultrasound; CT: Computed tomography; MRI: Magnetic resonance imaging; GIST: Gastrointestinal stromal tumour.

Table 2 Summary of clinical data from all 10 cases of mesenteric schwannomas

	n (%) or mean ± SD (range)
Age (yr) (n = 8)
Mean	52.89 ± 12.14 (38-80)
Sex (male/female), (male %) (n = 9)	4/5 (44.44%)
Symptoms (n = 10)
Asymptomatic	7 (70.00)
Symptomatic
Abdominal pain	3 (30.00)
Hematochezia	1 (10.00)
Nausea	1 (10.00)
Vomiting	1 (10.00)
Constipation	1 (10.00)
Mean size (cm) (n = 7)	8.86 ± 6.68 (2-22)
Operation (n = 9)
Laparotomy	6 (66.67)
Laparoscopic operation	2 (22.22)
Enucleation	1 (11.11)
Histology (n = 10)
Benign	10 (100.00)
Malignant	0 (0.00)
Follow-up (mo) (n = 8)	18.43 ± 12.00 (5-43)
Survived	7 (100.00)